Slimane A.
- Country
- France
- Department
- 1402: Département de Recherche Clinique
Research Overview
- FAMODREP : Interest of Famotidine in Reducing Endothelial Expression of P-selectin in Children With Sickle Cell Disease: Pilot Study, Single-center, Prospective, Non-comparative
- Phase IV, Open-label, Multi-center Rollover Study of Crizanlizumab in Patients with Sickle Cell Disease Post-Novartis-Sponsored Study Completion
- Evaluation of Tocilizumab Efficacy and Safety in Treating Acute Chest Syndrome in Pediatric and Adult Sickle Cell Disease Patients
Data & Insights
Has run more than one trial at 2 of 14 partner sites.
Specializations
Hematological Disorders
This investigator specializes in treating sickle cell disease (SCD), with particular focus on developing innovative therapeutic approaches for managing this chronic blood disorder.
- Acute Chest Syndrome Management
- Novel Treatment Protocols
- Pediatric and Adult SCD Care
The investigator explores various therapeutic agents targeting different aspects of SCD pathophysiology.
Immunological Interventions
The research focus includes investigating immunomodulatory treatments for SCD complications, particularly examining the role of targeted therapies in disease management.
- Endothelial Function Studies
- Anti-inflammatory Approaches
- P-selectin Expression Analysis
Their work examines the effectiveness of various immunological interventions in treating SCD manifestations.
Therapeutic Innovation
The investigator evaluates novel therapeutic agents for SCD treatment, including both established and experimental medications.
- Long-term Treatment Efficacy
- Respiratory Support Optimization
- Drug Response Assessment
Research encompasses various treatment modalities for managing acute and chronic SCD complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.